Foamix Receives USPTO Patents for Topical Tetracyclines

November 13, 2014

Foamix Pharmaceuticals Ltd., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that the United States Patent and Trademark Office ("USPTO") has recently issued to it two additional patents, namely U.S. Patent No. 8,865,139 and U.S. Patent No. 8,871,184, each entitled "Topical tetracycline compositions". Both patents are expected to remain in effect until 2030.
These two new patents relate to compositions of matter comprising claims to a tetracycline antibiotic formulation and its physical properties. The tetracycline antibiotic includes minocycline and doxycycline, which are the subject of Foamix's lead product candidates FMX101 and FMX102, comprising minocycline, and FDX104, comprising doxycycline. These patents also relate to methods of treatment of dermatological disorders, such as acne, impetigo and rosacea.
These patents add to and complement an earlier Foamix patent, U.S. Patent No., 8,618,081 entitled "Compositions, gels and foams with rheology modulators and uses thereof."
Foamix Pharmaceuticals currently has 73 granted patents and 114 patent applications worldwide. In the United States, Foamix has established a patent portfolio of 34 granted patents and 59 pending patent applications concerning our foam-based platforms and other technologies.

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free